Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
TG Therapeutics (NASDAQ: TGTX) reported Q1 2026 total global revenue of ~$205 million, including BRIUMVI U.S. net product revenue of $194.8 million. The company raised full-year 2026 revenue guidance to ~$925 million and increased BRIUMVI U.S. guidance to $885–900 million. TG secured $500 million of non-dilutive capital, expanded its buyback program to $300 million, and repurchased $200 million of shares to date. Cash, cash equivalents and investments were $572.8 million as of March 31, 2026. Key near-term milestones include ENHANCE topline data mid-2026 and subcutaneous BRIUMVI topline by year-end 2026/early 2027.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on Wednesday, May 6, 2026 at 8:30 AM ET to discuss first quarter 2026 financial results and provide a business outlook for the rest of 2026.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day audio replay will be available on the company's Investors & Media Events page. Financial results will be released in a press release prior to the call.
TG Therapeutics (NASDAQ: TGTX) announced presentations of data on BRIUMVI (ublituximab‑xiiy) for relapsing multiple sclerosis at the American Academy of Neurology 2026 annual meeting in Chicago on April 22, 2026.
Presentations cover real‑world outcomes from the Phase 4 ENABLE observational study and dosing/safety updates from the ENHANCE study; posters and links are available on the company Publications page.
TG Therapeutics (NASDAQ: TGTX) announced completion of enrollment in its Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab) for relapsing multiple sclerosis. The randomized, open-label non-inferiority study compares two SC dosing regimens (every 8 weeks and every 12 weeks) to the approved IV schedule.
The primary endpoint is non-inferior systemic exposure (AUC) at Week 24. Top-line data are expected around year-end 2026 or early 2027.
TG Therapeutics (NASDAQ: TGTX) secured a new five-year $750 million senior secured credit facility with funds managed by Blue Owl, repaid its prior $250 million facility and thus raised 500 million of net non-dilutive capital. The facility can be increased by $250 million to a total of $1 billion at mutual discretion.
The Board expanded the share repurchase program from $100 million to $300 million; as of March 18, 2026 the company repurchased about $38 million of stock at an average price of $28.98. Further credit-facility details will be filed on Form 8-K.
Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.
The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.
TG Therapeutics (NASDAQ: TGTX) published a post hoc pooled analysis from Phase 3 ULTIMATE I and II showing BRIUMVI (ublituximab) produced large, statistically significant reductions in relapses and MRI activity versus teriflunomide in people with highly active relapsing MS.
Key results: ARR 0.145 vs 0.496 (70.8% reduction), early and sustained lesion reductions through Week 96, and markedly higher NEDA-3 rates (77.9% vs 16.4% during Weeks 24–96).
TG Therapeutics (NASDAQ: TGTX) announced the schedule of data presentations for BRIUMVI (ublituximab-xiiy) at the American Academy of Neurology (AAN) 2026 annual meeting, April 18–22 in Chicago. Two poster presentations on April 21 cover real-world ENABLE Phase 4 experience and ENHANCE safety/tolerability updates. Abstracts are available on the AAN website and data will be posted to the company publications page.
Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.
The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.